Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 3/20 | 0.32 |
| ▸ | CCR2 | P41597 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696579 | 0.91 | RXFP1 (0.34) | RXFP1CCR1CCR2ALOX15TSHR | |
| SCHEMBL698378 | 0.86 | CCR1 (0.32) | RXFP1CCR1CCR2ALOX15TSHR | |
| SCHEMBL13148379 | 0.82 | RXFP1 (0.36) | RXFP1CCR1CCR2MAOBPDE3B | |
| SCHEMBL13148515 | 0.81 | MAP2K1 (0.30) | — | |
| SCHEMBL693627 | 0.80 | MAOB (0.30) | MAOB | |
| SCHEMBL13628793 | 0.79 | MAPT (0.35) | RXFP1MAOBPDE3BPDE3A | |
| SCHEMBL13613839 | 0.78 | RXFP1 (0.35) | RXFP1ALOX15TSHRMAOBPDE3B | |
| SCHEMBL711027 | 0.74 | USP30 (0.35) | RXFP1CCR1CCR2PDE3BPDE3A | |
| SCHEMBL692885 | 0.74 | RXFP1 (0.35) | RXFP1CCR1CCR2ALOX15TSHR | |
| SCHEMBL693391 | 0.74 | MEN1 (0.35) | RXFP1CCR1CCR2MAOBPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | RXFP1 4597/4885CCR1 970/4885CCR2 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.